CN102086223B - Method for preparing ginsenoside Rg1 - Google Patents
Method for preparing ginsenoside Rg1 Download PDFInfo
- Publication number
- CN102086223B CN102086223B CN200910241758.3A CN200910241758A CN102086223B CN 102086223 B CN102086223 B CN 102086223B CN 200910241758 A CN200910241758 A CN 200910241758A CN 102086223 B CN102086223 B CN 102086223B
- Authority
- CN
- China
- Prior art keywords
- ginsenoside
- elutriant
- ethanol elution
- dry
- discards
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 title claims abstract description 34
- 238000000034 method Methods 0.000 title abstract description 39
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 title abstract description 6
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 title abstract description 6
- 229930182494 ginsenoside Natural products 0.000 claims abstract description 57
- 229940089161 ginsenoside Drugs 0.000 claims abstract description 57
- 229920005989 resin Polymers 0.000 claims abstract description 27
- 239000011347 resin Substances 0.000 claims abstract description 27
- 238000000605 extraction Methods 0.000 claims abstract description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 94
- 238000010828 elution Methods 0.000 claims description 48
- 229930182490 saponin Natural products 0.000 claims description 41
- 150000007949 saponins Chemical class 0.000 claims description 41
- 235000017709 saponins Nutrition 0.000 claims description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 32
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 28
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 28
- 239000000047 product Substances 0.000 claims description 26
- 239000012141 concentrate Substances 0.000 claims description 25
- 230000000274 adsorptive effect Effects 0.000 claims description 23
- 238000001035 drying Methods 0.000 claims description 23
- 239000000706 filtrate Substances 0.000 claims description 23
- -1 filter Substances 0.000 claims description 22
- 238000002360 preparation method Methods 0.000 claims description 22
- 238000005406 washing Methods 0.000 claims description 22
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 21
- 235000008434 ginseng Nutrition 0.000 claims description 21
- 238000010438 heat treatment Methods 0.000 claims description 21
- 238000010992 reflux Methods 0.000 claims description 21
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 20
- 244000131316 Panax pseudoginseng Species 0.000 claims description 15
- 239000000284 extract Substances 0.000 claims description 14
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims description 12
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 12
- 241000180649 Panax notoginseng Species 0.000 claims description 10
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 10
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 claims description 9
- 240000005373 Panax quinquefolius Species 0.000 claims description 7
- 240000006509 Gynostemma pentaphyllum Species 0.000 claims description 2
- 239000000463 material Substances 0.000 abstract description 16
- 239000003960 organic solvent Substances 0.000 abstract description 10
- 238000012360 testing method Methods 0.000 abstract description 7
- 230000000144 pharmacologic effect Effects 0.000 abstract description 4
- 238000000638 solvent extraction Methods 0.000 abstract description 4
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 230000007721 medicinal effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 22
- 238000002474 experimental method Methods 0.000 description 21
- 239000000243 solution Substances 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- 241000208340 Araliaceae Species 0.000 description 18
- 239000000825 pharmaceutical preparation Substances 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 9
- 238000003672 processing method Methods 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 206010008118 cerebral infarction Diseases 0.000 description 8
- 239000000470 constituent Substances 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 241001065361 Gynostemma Species 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000004224 protection Effects 0.000 description 7
- 208000026106 cerebrovascular disease Diseases 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 201000006474 Brain Ischemia Diseases 0.000 description 5
- 206010008120 Cerebral ischaemia Diseases 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 230000001338 necrotic effect Effects 0.000 description 5
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 210000000269 carotid artery external Anatomy 0.000 description 4
- 210000004004 carotid artery internal Anatomy 0.000 description 4
- 208000031225 myocardial ischemia Diseases 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 239000013558 reference substance Substances 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 206010063837 Reperfusion injury Diseases 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 230000000703 anti-shock Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000003727 cerebral blood flow Effects 0.000 description 2
- 229920001429 chelating resin Polymers 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 210000003746 feather Anatomy 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 238000011005 laboratory method Methods 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 241000237970 Conus <genus> Species 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010018833 Haematocoele Diseases 0.000 description 1
- 208000005873 Hematocele Diseases 0.000 description 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 235000005769 Japanese ginseng Nutrition 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000007201 Myocardial reperfusion injury Diseases 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 241000168720 Panax japonicus Species 0.000 description 1
- 235000003174 Panax japonicus Nutrition 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000002364 anti-haemorrhagic effect Effects 0.000 description 1
- 230000002019 anti-mutation Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000002223 garnet Substances 0.000 description 1
- 239000010437 gem Substances 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 201000004920 hematocele of tunica vaginalis testis Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 210000000876 intercostal muscle Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Abstract
The invention discloses a method for preparing a ginsenoside Rg1 active ingredient, which is characterized in that: total ginsenoside is extracted from different medicinal materials and the ginsenoside Rg1 with the purity of more than or equal to 95 percent is obtained by a method combining macroporous adsorbing resin and organic solvent extraction. The method is suitable for industrial production, kilogram-grade ginsenoside Rg1 can be obtained and the method has the characteristics of high extraction efficiency, low consumption of organic solvent and the like; and pharmacological tests prove that the ginsenoside Rg1 prepared by the method has good medicinal effect.
Description
Technical field
The present invention relates to technical field of traditional Chinese medicines, be specifically related to a kind of ginsenoside Rg
1the preparation method of effective constituent.
Background technology
Ginsenoside Rg
1be mainly derived from Araliaceae Panax ginseng, pseudo-ginseng, Radix Panacis Quinquefolii, Vietnam's ginseng, rhizome of Japanese Ginseng; in the roots of the plants such as Curcurbitaceae gynostemma pentaphyllum genus gynostemma pentaphylla, edge fruit gynostemma pentaphylla, stem, leaf, bud; there is good pharmacologically active: (1) provide protection to myocardial ischemia-reperfusion; research shows, ginsenoside Rg
1can reduce the damage of SD suckling mouse Ischemic Myocardial Cells, the provide protection of performance to myocardial ischemia-reperfusion; (2) provide protection to cerebral ischemia, ginsenoside Rg
1can increase cerebral blood flow (CBF) by improving Animal Microcirculation, performance improves the effect of cerebral ischemia; (3) there is anti thrombotic action, ginsenoside Rg
1can obviously reduce experimental thrombosis and form, platelet aggregation that can anticoagulant enzyme induction; (4) there is anti-mutation and antitumor action, ginsenoside Rg
1the DNA damage of somatocyte and sexual cell is all had to provide protection, mice transplanted tumor is also had to certain tumor-inhibiting action; (5) there is antifatigue and resisting oxygen lack, ginsenoside Rg
1mouse anti-reflecting fatigue and hypoxia tolerance are had to obvious effect; (6) there is the effect of anti-hemorrhagic shock; Etc..
In sum, ginsenoside Rg
1have significantly and widely pharmacologically active, patent medicine basis is good.But prepare at present ginsenoside Rg
1method mostly be laboratory method, only can obtain a small amount of ginsenoside Rg
1(mg level is to g level), for scientific research, is difficult to obtain the ginsenoside Rg of level (feather weight) in batches
1, therefore, first explore and can suitability for industrialized production obtain the ginsenoside Rg of level in batches
1preparation technology, be ginsenoside Rg
1can key that patent medicine and basis, have important technology and marketable value; Its two, obtaining in batches level high-content ginsenoside Rg
1basis on, further improve its quality, make it obtain comprehensive mass of system control, the medicine that it is made as activeconstituents, steady quality, curative effect is controlled with safety, is that Chinese medicine moves towards the basis requirement of international inherence; Its three, ginsenoside Rg
1as curative effect composition, dose-effect/time-effect relationship, drug disposition dynamic metabolism and security it be unclear that, need to screen and the research such as pharmacokinetics by dose-effect, optimize its excellent effect dosage and administering mode, and these systems further investigations all need the ginsenoside Rg of level in batches
1for basis; Therefore, set up preparation grade ginseng saponin(e Rg in batches through technological innovation
1processing method, be the technical guarantee of follow-up study, needing scientific research personnel to pay huge creative work could realize.
Application number is 03148804.8 patent documentation, and the method that the document discloses employing silica gel (or aluminum oxide) column chromatography obtains ginsenoside Rg
1; Application number is 200610093615.9,200610093610.6 patent documentation, and the document discloses and adopted the method for silica gel column chromatography, alumina column chromatography or ODS column chromatography can obtain ginsenoside Rg
1; These class methods involve great expense, and are only applicable to laboratory study, are difficult to realize suitability for industrialized production.
Summary of the invention
For these reasons, our scientific research personnel studies by scientific experiment, has invented a kind of applicable suitability for industrialized production, processing method that extraction yield is high, for extracting purified ginsenoside Rg
1, the method adopts Flavonoids by Macroporous Adsorption Resin and organic solvent extraction method to carry out organic assembling, and the total saponins that different medicinal materials are obtained further extracts purifying, obtains ginsenoside Rg
1content is more than or equal to 95%, can be for developing a kind new medicine, and have that yield is high, organic solvent uses the features such as few, can obtain the ginsenoside Rg of feather weight
1, the ginsenoside Rg who makes
1patent medicine research has had good basic substance.
The present invention is achieved through the following technical solutions.
(1) get pseudo-ginseng, ginseng, Radix Panacis Quinquefolii or gynostemma pentaphylla and extract the total saponins obtaining, total saponins is dissolved in water;
(2) lysate filters, and filtrate, by nonpolar or low-pole macroporous resin macroporous adsorptive resins, is washed, elutriant discards, 25%-35% ethanol elution, elutriant discards, then uses 40% ethanol elution, collect elutriant, concentrate drying, dry product adds organic solvent extraction, and extracting solution filters, residue is dry, obtains ginsenoside Rg
1.
Wherein the nonpolar or low-pole macroporous resin described in preparation method includes but not limited to: HPD-100, HPD-100A, HPD-300, HPD-400, HPD-400A, HPD-450, D101,1300-I, 1400 or AB-8.
Wherein the organic solvent described in preparation method includes but not limited to as the one in acetone, butanone.
Total saponins in said extracted method can directly be bought by market or prepare according to scientific and technical literature.
Ginsenoside Rg prepared by aforesaid method
1the pharmaceutical preparation of the unitary dose of preparing for active substance.
Ginsenoside Rg prepared by aforesaid method
1treat and/or prevent the application in the medicines such as cardiovascular and cerebrovascular diseases, antishock, antitumor, anti-ageing, hypomnesis in preparation.
One, ginsenoside Rg
1content assaying method and detected result
Experimental technique: adopt high performance liquid chromatography to carry out assay;
Chromatographic column: C
18reverse-phase chromatographic column; Chromatographic condition and system suitability experiment: take octadecylsilane chemically bonded silica as weighting agent; Flow velocity 1.0ml/min; 25 ℃ of column temperatures; Detect wavelength 203nm; Number of theoretical plate is by ginsenoside Rg
1meter should be not less than 2500; Take water: acetonitrile, as moving phase, carries out gradient elution by following condition of gradient elution, moves 60 minutes;
0-40 minute time, the ratio of water is down to 50% by 80%, and the ratio of acetonitrile rises to 50% by 20%; 40-43 minute time, the ratio of water is down to 20% by 50%, and the ratio of acetonitrile rises to 80% by 50%; 43-48 minute time, keeping the ratio of water is 20%, and keeping the ratio of acetonitrile is 80%; 48-50 minute time, water ratio rises to 80% by 20%, and the ratio of acetonitrile is down to 20% by 80%; 50-60 minute keeps the ratio of water is 20%, the ratio 80% of acetonitrile;
The preparation of reference substance solution: precision takes ginsenoside Rg
1reference substance, in volumetric flask, adds dissolve with methanol and shakes up, and is diluted to scale;
The preparation of need testing solution: precision takes sample and shakes up to adding dissolve with methanol in volumetric flask, and is diluted to scale;
Assay method: accurate absorption reference substance solution and need testing solution are each respectively, injection liquid chromatography, adopts and presses external standard method with calculated by peak area, to obtain final product.
Note: ginseng saponin(e Rg of the present invention
1reference substance is legal product, buys from Chinese pharmaceutical biological product and identifies institute.
Get the ginsenoside Rg that preparation method of the present invention obtains
1effective constituent, detects analysis according to above-mentioned experimental technique.
Experimental result: the results are shown in Table 1:
Table 1 ginsenoside Rg
1sample determination result
Experiment conclusion: show ginseng saponin(e Rg of the present invention by above-mentioned experiment
1content is more than or equal to 95%, absolutely proves that processing method of the present invention has scientific meaning.
Two, different process method contrast experiment
Experimental program:
Scheme 1: the Chinese patent that application number is 03148804.8, disclosed embodiment in specification sheets;
Scheme 2: the Chinese patent that application number is 200610093615.9, disclosed embodiment 1 and embodiment 7 in specification sheets;
Scheme 3: the Chinese patent that application number is 200610093610.6, disclosed embodiment 1 and embodiment 7 in specification sheets;
Scheme 4: processing method of the present invention.
Experimental technique, gets the Radix Notoginseng total arasaponins of same batch, tests according to above-mentioned experimental program, obtains ginsenoside Rg
1.
Experimental result: the results are shown in Table 2.
The comparative experiments of table 2 different process method
Discuss: the method that experimental program 1,2 and 3 adopts is: Amberlyst process+silica gel for total saponins (or aluminum oxide) column chromatography+silica gel column chromatography, obtains ginsenoside Rg
1the method is used two step silica gel (aluminum oxide) column chromatographies, use mixed solvent and consumption of organic solvent large, solvent is difficult to recycling, and the regeneration of silica gel (aluminum oxide) is difficulty comparatively, and silica gel (or aluminum oxide) column chromatography is generally as laboratory method, prepare micro-product for scientific research, for suitability for industrialized production, product cost is very high, and human consumer is difficult to bear; Ginsenoside Rg
1be mainly used in cardiovascular and cerebrovascular diseases aspect, the time that patient uses is long, if produce ginsenoside Rg
1processing method numerous and diverse, cost is higher, can bring huge economical load to patient; What scheme 4 (processing method of the present invention) adopted is Amberlyst process+organic solvent extraction method, the organic solvent that the method adopts is single organic solvent-acetone or butanone, toxicity is little, be beneficial to recycling, and the amount using is also less, the method technique is simple, economical, is suitable for suitability for industrialized production.
Conclusion: show by above-mentioned experiment, the poisonous organic solvent amount that processing method of the present invention is used is few, low to operating space requirement, environmental pollution is less, has the advantages that yield is high, absolutely proves that processing method of the present invention has scientific meaning.
Note: the total saponins of the medicinal materials such as above-mentioned Radix Notoginseng total arasaponins and ginseng, gynostemma pentaphylla, Radix Panacis Quinquefolii is replaced, and experiment conclusion is identical with above-mentioned experiment conclusion.
Three, pharmacological effect experiment
The provide protection of 1 pair of anesthetized rat myocardial ischemia-reperfusion injury of experiment.
Laboratory animal: healthy SD rat, body weight 240-260g.
Experimental agents: physiological saline; Ginseng saponin(e Rg of the present invention
1effective constituent.
Experiment reagent: 20% urethane is pressed; The tincture of iodine; Test kit; 1%TTC.
Laboratory apparatus: respirator; Electrocardiograph; Ophthalmic tweezers; Automatic clinical chemistry analyzer; Digital camera.
Experimental technique: by rat random packet: model group, ginseng saponin(e Rg of the present invention
1group.Be placed in the pre-raising of equivalent environment 2 days, free diet.After pre-raising finishes, test, animal is weighed, and 20% urethane is pressed 0.6ml/100g abdominal injection, after anesthesia is satisfied, to lie on the back and be fixed on mouse plate, trachea cannula, connects respirator, by 10～12ml Tidal volume, the frequency of 70 beats/min is exhaled, and continuous positive pressure breathing is inhaled: exhale than being 1: 1.Adjust respiration parameter according to respiratory rate and the degree of depth.Connect subsequently electrocardiograph, survey normal ECG.Cut off front field of operation hair, iodine disinfection, cut off skin, subcutis, front muscle and manadesma 3～4cm, long along the 3rd intercostal blunt separation intercostal muscle 3cm with 18# vascular clamp, open thoracic cavity and pericardium, recording ecg, strut 3, 4 ribs, hold Rat Right pleurobranch chamber with left hand four fingers, assistant upwards pushes away thymus gland with ophthalmic tweezers, between left auricle of heart and pulmonary conus, find ligation mark blood vessel great cardiac vein, nothing wound roundlet pin band 6-0 silk thread threading for 2mm place below left auricle of heart, depth of needle is 1～1.5mm, wide 2～3mm, recording ecg after threading, give corresponding liquid through tail vein, recording ecg after administration 10min, and with one the little plastics pipe pad with groove at ligation position, the ligation thereon of two rear line heads.At once recording ecg after ligation, is cyanosis or the II S-T section back of a bow that leads take left chamber antetheca and upwards raises and be greater than 0.1mv and continue 0.5h above for ligation successfully indicates (S-T section is superseded without changer).After ligation, 10min recording ecg again, cuts off ligature after ligation 30min, realizes and pouring into, and record and pour into electrocardiogram(ECG at once again, and in removing thoracic cavity, the layer-by-layer suture wall of the chest after hematocele, removes respirator, and animal recovers autonomous respiration, and incision of trachea does not process.Fill with at once again, 10min, 20min, 40min, 1h, 2h, 3h recording ecg respectively.Fill with again 3 hours, through abdominal aortic blood, 4000rpm is centrifugal, and 10min gets serum, adopt automatic clinical chemistry analyzer to detect LDH, CK and CK-MB activity, and adopt corresponding reagent box to detect SOD in serum, MDA (the concrete detecting step of above index refers to specification sheets), and dissection is cored dirty, and ice physiological saline washes away residual blood, cut off atrium and right ventricle, put into immediately refrigerator and cooled and freeze.Heart is frozen after 10min in refrigerator and cooled, from the parallel coronary sulcus direction in the centripetal end of the apex of the heart, left chamber is cut into 5 of equal thickness, put into 1 %TTC dye liquor, 37 ℃ of dyeing 10min, necrotic area is not garnet, necrotic area is canescence.Digital camera is taken pictures.Weighed respectively in He Fei necrotic area, necrotic area, calculating necrotic area accounts for the per-cent of left ventricular mass, i.e. infarction size.
Experimental result: the results are shown in Table 3.
Table 3 is on ligation/impact of logical rat ramus descendens anterior arteriae coronariae sinistrae Myocardial Ischemia/reperfusion injury myocardial infarct size (%) again
Note: * * P < 0.01 compared with model group.
The research of 2 pairs of focal cerebral ischemia-reperfusion Injury model of Wistar rats provide protections of experiment
Laboratory animal: wistar rat, male, body weight is in 250g left and right.
Experimental agents: physiological saline; Ginseng saponin(e Rg of the present invention
1effective constituent.
Experiment reagent: heparin; Formaldehyde; TTC dye liquor.
Laboratory apparatus: balance; Vacuum drier; Refrigerator.
Experimental technique: by animal random packet: blank group, ginseng saponin(e Rg of the present invention
1group of effective components.Ginseng saponin(e Rg of the present invention
1the each 8.0mg/kg of group of effective components dosage, blank group gives physiological saline.Administration group and control group successive administration 3 days, every day 1 time.Within after the 4th day medicine 20 minutes, make middle cerebral artery occlusion (MCAO) model by improvement line bolt method.After rat anesthesia, lain on the back fixing.Separate right carotid (CCA), internal carotid artery (ICA) and external carotid artery (ECA), ligation ECA and CCA, press from both sides and close after ICA distal end with bulldog clamp, make a kerf in ECA and ICA crotch rapidly, insert one end and be heated into smooth, spherical and be coated with the nylon wire of 0.1% poly-lysine that (diameter is 0.25mm, apart from pommel, 18mm place marks, before insertion, be stained with heparin solution), depth of penetration is 18mm, realizes middle cerebral artery occlusion and causes cerebral ischemia.Ligation ingress, nylon wire stays about 1cm, skin suture outward.After 2 hours, lift gently extremely slightly resistance of stayed the end of a thread, realize arteria cerebri media and pour into, modeling completes.At ischemic 2h with pour into the body temperature that maintains rat in 1h with electric blanket, body temperature maintains 36.5～37.5 ℃ of anus temperature again.Animal inclusion criteria, by Longa Pyatyi point system, gets neural function behavior scoring and is the animal of 1,2,3,4 point, (0 point: impassivity defective symptom; 1 point: offside forelimb can not stretch completely; 2 points: to sideway swivel; 3 points: topple over to offside; 4 points: can not oneself walk or stupor).Range of Cerebral Infarction is measured, rat model pours into 24h again, after study of behaviour scoring, broken end is got brain, removes olfactory bulb, cerebellum and low brain stem, and remainder is at-20 ℃ of refrigerator freezing 10min, crownly on ice pan be cut into 6, rapidly brain sheet is placed in to TTC dye liquor, 37 ℃ of lucifuge temperature are incubated 1h, take out and are placed on the 24h that keeps in Dark Place in 10% formalin.Dyed rear non-ischemic region is rose, and infarct is white.White is organized carefully and dug down and weigh, account for full brain weight per-cent as Range of Cerebral Infarction using blocking tissue's weight.
Brain water content is measured: after TTC dyeing is weighed, brain is placed in and in 120 ℃ of vacuum driers, dries 12h and claim dry weight.Brain water content=(brain weight in wet base-brain stem weight)/brain weight in wet base × 100%.
Experimental result: the results detailed in Table 4.
The impact of table 4 on focal cerebral ischemia-reperfusion Injury model of Wistar rats rat cerebral infarction scope and brain water content
Note: with relatively * * P < 0.01 of blank group.
Note: ginsenoside Rg prepared by the inventive method
1the pharmacological effect experiment of the aspects such as that effective constituent is carried out is antitumor, antishock, anti-ageing, hypomnesis, result shows, ginsenoside Rg prepared by the inventive method
1effective constituent and control group have utmost point significant difference (P < 0.01).
Experiment conclusion: test and show by pharmacological effect, ginsenoside Rg prepared by the inventive method
1effective constituent and control group relatively have utmost point significant difference (P < 0.01), absolutely prove that processing method of the present invention has practical significance.
Four, Preparation Example
Embodiment 1
Get pseudo-ginseng and extract the Radix Notoginseng total arasaponins obtaining and be dissolved in water, filter, filtrate is by HPD-400A macroporous adsorptive resins, washing, elutriant discards, 25% ethanol elution, elutriant discards, use again 40% ethanol elution, collect elutriant, concentrate drying, the acetone heating and refluxing extraction of dry product, extracting solution filters, and residue is dry, obtains ginsenoside Rg
1.
The method that pseudo-ginseng is extracted total saponins is prepared according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside is as Rg
1medicine material, can be prepared into acceptable pharmaceutical preparation in pharmaceutics.
Embodiment 2
Get ginseng and extract the total saponins obtaining and be dissolved in water, filter, filtrate is by HPD-400 macroporous adsorptive resins, washing, elutriant discards, 30% ethanol elution, elutriant discards, use again 40% ethanol elution, collect elutriant, concentrate drying, the butanone heating and refluxing extraction of dry product, extracting solution filters, and residue is dry, obtains ginsenoside Rg
1.
Described Radix Ginseng total saponins extracting method is prepared according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1as medicine material, can be prepared into acceptable pharmaceutical preparation in pharmaceutics.
Embodiment 3
Get Radix Panacis Quinquefolii and extract and obtain total saponins and be dissolved in water, filter, filtrate is by HPD-300 macroporous adsorptive resins, washing, elutriant discards, 35% ethanol elution, elutriant discards, use again 40% ethanol elution, collect elutriant, concentrate drying, the propyl carbinol of dry product, ethanol, methyl alcohol heating and refluxing extraction, extracting solution filters, and residue is dry, obtains ginsenoside Rg
1.
Described American ginseng total saponins extracting method is prepared according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1as medicine material, can be prepared into acceptable pharmaceutical preparation in pharmaceutics.
Embodiment 4
Get pseudo-ginseng and extract the total saponins obtaining and be dissolved in water, filter, filtrate is by HPD-450 macroporous adsorptive resins, washing, elutriant discards, 25% ethanol elution, elutriant discards, use again 50% ethanol elution, collect elutriant, concentrate drying, add organic solvent-acetone to extract, extracting solution filters, and residue is dry, obtains ginsenoside Rg
1.
The extracting method of described Radix Notoginseng total arasaponins can lead to according to existing patent documentation or scientific and technical literature and is prepared.
Above-mentioned ginsenoside Rg
1as medicine material, can be prepared into acceptable pharmaceutical preparation in pharmaceutics.
Embodiment 5
Get gynostemma total saponin and be dissolved in water, filter, filtrate is by HPD-100A macroporous adsorptive resins, washing, elutriant discards, 30% ethanol elution, elutriant discards, use again 50% ethanol elution, collect elutriant, concentrate drying, the butanone heating and refluxing extraction of dry product, extracting solution filters, and residue is dry, obtains ginsenoside Rg
1.
Described gynostemma total saponin prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1as medicine material, can be prepared into acceptable pharmaceutical preparation in pharmaceutics.
Embodiment 6
Get Radix Ginseng total saponins and be dissolved in water, filter, filtrate is by D101 macroporous adsorptive resins, washing, elutriant discards, 35% ethanol elution, elutriant discards, use again 50% ethanol elution, collect elutriant, concentrate drying, the acetone heating and refluxing extraction of dry product, extracting solution filters, and residue is dry, obtains ginsenoside Rg
1.
Described Radix Ginseng total saponins prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1as medicine material, can be prepared into acceptable pharmaceutical preparation in pharmaceutics.
Embodiment 7
Get American ginseng total saponins and be dissolved in water, filter, filtrate is by HPD-100A macroporous adsorptive resins, washing, elutriant discards, 25% ethanol elution, elutriant discards, use again 45% ethanol elution, collect elutriant, concentrate drying, the butanone heating and refluxing extraction of dry product, extracting solution filters, and residue is dry, obtains ginsenoside Rg
1.
Described American ginseng total saponins is by commercially available purchase.
Above-mentioned ginsenoside Rg
1as medicine material, can be prepared into acceptable pharmaceutical preparation in pharmaceutics.
Embodiment 8
Get Radix Notoginseng total arasaponins and be dissolved in water, filter, filtrate is by 1300-I macroporous adsorptive resins, washing, elutriant discards, 30% ethanol elution, elutriant discards, use again 45% ethanol elution, collect elutriant, concentrate drying, the acetone heating and refluxing extraction of dry product, extracting solution filters, and residue is dry, obtains ginsenoside Rg
1.
Described Radix Notoginseng total arasaponins prepares (Yang Chongren, kingdom swallow, 5 jewels, etc., the saponin component of pseudo-ginseng reed head, pharmacy circular, 1985,20 (6): 337-338) according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1as medicine material, can be prepared into acceptable pharmaceutical preparation in pharmaceutics.
Embodiment 9
Get ginseng and extract the total saponins obtaining and be dissolved in water, filter, filtrate is by HPD-100 macroporous adsorptive resins, washing, elutriant discards, 35% ethanol elution, elutriant discards, concentrate, use again 45% ethanol elution, collect elutriant, concentrate drying, the butanone heating and refluxing extraction of dry product, extracting solution filters, and residue is dry, obtains ginsenoside Rg
1.
Described Radix Ginseng total saponins extracting method prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1as medicine material, can be prepared into acceptable pharmaceutical preparation in pharmaceutics.
Embodiment 10
Get American ginseng total saponins and be dissolved in water, filter, filtrate is by 1400 macroporous adsorptive resins, washing, elutriant discards, 30% ethanol elution, elutriant discards, use again 40% ethanol elution, collect elutriant, concentrate drying, the acetone heating and refluxing extraction of dry product, extracting solution filters, and residue is dry, obtains ginsenoside Rg
1.
Described American ginseng total saponins prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1as medicine material, can be prepared into acceptable pharmaceutical preparation in pharmaceutics.
Embodiment 11
Get pseudo-ginseng and extract and obtain total saponins and be dissolved in water, filter, filtrate is by AB-8 macroporous adsorptive resins, washing, elutriant discards, 30% ethanol elution, elutriant discards, use again 40% ethanol elution, collect elutriant, concentrate drying, the acetone heating and refluxing extraction of dry product, extracting solution filters, and residue is dry, obtains ginsenoside Rg
1.
Described Radix Notoginseng total arasaponins extracting method prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1as medicine material, can be prepared into acceptable pharmaceutical preparation in pharmaceutics.
Embodiment 12
Get pseudo-ginseng and extract and obtain total saponins and be dissolved in water, filter, filtrate is by AB-8 macroporous adsorptive resins, washing, elutriant discards, 35% ethanol elution, elutriant discards, use again 45% ethanol elution, collect elutriant, concentrate drying, the acetone heating and refluxing extraction of dry product, extracting solution filters, and residue is dry, obtains ginsenoside Rg
1.
Described Radix Notoginseng total arasaponins prepares according to existing patent documentation or scientific and technical literature.
Above-mentioned ginsenoside Rg
1as medicine material, can be prepared into acceptable pharmaceutical preparation in pharmaceutics.
Above-described embodiment 1-12 obtains ginsenoside Rg
1in effective constituent, ginsenoside Rg
1purity is more than or equal to 95%.
Above-mentioned ginsenoside Rg
1treat and/or prevent the application in cardiovascular and cerebrovascular diseases, antishock, antitumor, anti-ageing, hypomnesis medicine in preparation.
Above-mentioned pseudo-ginseng, ginseng, Radix Panacis Quinquefolii, gynostemma pentaphylla can be medicinal material root, stem, leaf, the bud in the different places of production.
Note: the present invention's concrete technical scheme required for protection, is not limited to the concrete combination of the expressed technical scheme of above-described embodiment.
Claims (10)
1. a ginsenoside Rg
1preparation method, it is characterized by:
Get pseudo-ginseng and extract the Radix Notoginseng total arasaponins obtaining and be dissolved in water, filter, filtrate is by HPD-400A macroporous adsorptive resins, washing, elutriant discards, 25% ethanol elution, elutriant discards, use again 40% ethanol elution, collect elutriant, concentrate drying, dry product adds acetone heating and refluxing extraction, extracting solution filters, and residue is dry, obtains ginsenoside Rg
1.
2. a ginsenoside Rg
1preparation method, it is characterized by:
Get ginseng and extract the total saponins obtaining and be dissolved in water, filter, filtrate is by HPD-400 macroporous adsorptive resins, washing, elutriant discards, 30% ethanol elution, elutriant discards, use again 40% ethanol elution, collect elutriant, concentrate drying, dry product adds butanone heating and refluxing extraction, extracting solution filters, and residue is dry, obtains ginsenoside Rg
1.
3. a ginsenoside Rg
1preparation method, it is characterized by:
Get gynostemma total saponin and be dissolved in water, filter, filtrate is by HPD-100A macroporous adsorptive resins, washing, elutriant discards, 30% ethanol elution, elutriant discards, use again 50% ethanol elution, collect elutriant, concentrate drying, dry product adds butanone heating and refluxing extraction, extracting solution filters, and residue is dry, obtains ginsenoside Rg
1.
4. a ginsenoside Rg
1preparation method, it is characterized by:
Get Radix Ginseng total saponins and be dissolved in water, filter, filtrate is by D101 macroporous adsorptive resins, washing, elutriant discards, 35% ethanol elution, elutriant discards, use again 50% ethanol elution, collect elutriant, concentrate drying, dry product adds acetone heating and refluxing extraction, extracting solution filters, and residue is dry, obtains ginsenoside Rg
1.
5. a ginsenoside Rg
1preparation method, it is characterized by:
Get American ginseng total saponins and be dissolved in water, filter, filtrate is by HPD-100A macroporous adsorptive resins, washing, elutriant discards, 25% ethanol elution, elutriant discards, use again 45% ethanol elution, collect elutriant, concentrate drying, dry product adds butanone heating and refluxing extraction, extracting solution filters, and residue is dry, obtains ginsenoside Rg
1.
6. a ginsenoside Rg
1preparation method, it is characterized by:
Get Radix Notoginseng total arasaponins and be dissolved in water, filter, filtrate is by 1300-I macroporous adsorptive resins, washing, elutriant discards, 30% ethanol elution, elutriant discards, use again 45% ethanol elution, collect elutriant, concentrate drying, dry product adds acetone heating and refluxing extraction, extracting solution filters, and residue is dry, obtains ginsenoside Rg
1.
7. a ginsenoside Rg
1preparation method, it is characterized by:
Get ginseng and extract the total saponins obtaining and be dissolved in water, filter, filtrate is by HPD-100 macroporous adsorptive resins, washing, elutriant discards, 35% ethanol elution, elutriant discards, concentrate, use again 45% ethanol elution, collect elutriant, concentrate drying, dry product adds butanone heating and refluxing extraction, extracting solution filters, and residue is dry, obtains ginsenoside Rg
1.
8. a ginsenoside Rg
1preparation method, it is characterized by:
Get American ginseng total saponins and be dissolved in water, filter, filtrate is by 1400 macroporous adsorptive resins, washing, elutriant discards, 30% ethanol elution, elutriant discards, use again 40% ethanol elution, collect elutriant, concentrate drying, dry product adds acetone heating and refluxing extraction, extracting solution filters, and residue is dry, obtains ginsenoside Rg
1.
9. a ginsenoside Rg
1preparation method, it is characterized by:
Get pseudo-ginseng and extract and obtain total saponins and be dissolved in water, filter, filtrate is by AB-8 macroporous adsorptive resins, washing, elutriant discards, 30% ethanol elution, elutriant discards, use again 40% ethanol elution, collect elutriant, concentrate drying, dry product adds acetone heating and refluxing extraction, extracting solution filters, and residue is dry, obtains ginsenoside Rg
1.
10. a ginsenoside Rg
1preparation method, it is characterized by:
Get pseudo-ginseng and extract and obtain total saponins and be dissolved in water, filter, filtrate is by AB-8 macroporous adsorptive resins, washing, elutriant discards, 35% ethanol elution, elutriant discards, use again 45% ethanol elution, collect elutriant, concentrate drying, dry product adds acetone heating and refluxing extraction, extracting solution filters, and residue is dry, obtains ginsenoside Rg
1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910241758.3A CN102086223B (en) | 2009-12-07 | 2009-12-07 | Method for preparing ginsenoside Rg1 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910241758.3A CN102086223B (en) | 2009-12-07 | 2009-12-07 | Method for preparing ginsenoside Rg1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102086223A CN102086223A (en) | 2011-06-08 |
| CN102086223B true CN102086223B (en) | 2014-07-02 |
Family
ID=44098245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910241758.3A Active CN102086223B (en) | 2009-12-07 | 2009-12-07 | Method for preparing ginsenoside Rg1 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102086223B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105311045A (en) * | 2014-07-31 | 2016-02-10 | 天士力制药集团股份有限公司 | Application of ginsenoside Rg1 to preparation of medicines for prevention and/or treatment of myocardial ischemia |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1414011A (en) * | 2002-10-17 | 2003-04-30 | 南开大学 | Extraction method of notoginsenoside |
-
2009
- 2009-12-07 CN CN200910241758.3A patent/CN102086223B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1414011A (en) * | 2002-10-17 | 2003-04-30 | 南开大学 | Extraction method of notoginsenoside |
Non-Patent Citations (4)
| Title |
|---|
| 大孔吸附树脂纯化人参皂苷类成分的工艺研究;王辉等;《中国药房》;20090830;第20卷(第24期);第1865-1867页 * |
| 王辉等.大孔吸附树脂纯化人参皂苷类成分的工艺研究.《中国药房》.2009,第20卷(第24期),第1865-1867页. |
| 红参中人参总皂苷的提取纯化工艺研究;谢丽玲等;《中药材》;20091025;第32卷(第10期);第1602-1605页 * |
| 谢丽玲等.红参中人参总皂苷的提取纯化工艺研究.《中药材》.2009,第32卷(第10期),第1602-1605页. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102086223A (en) | 2011-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101311160B (en) | Method for preparing red sage root salviandic acid A | |
| CN105250366B (en) | Dracocephalum moldavica extract and preparation method and application thereof | |
| CN101597314B (en) | Preparation method of ginsenoside Rg1 | |
| CN101230003A (en) | Preparation method of salvia miltiorrhiza tanshinoate A | |
| CN101006984B (en) | An injection preparation containing salvianolic acid A and extract of panax natoginseng, and its preparation method and application | |
| CN104435034A (en) | PNS (panax notoginseng saponins) and preparation method thereof | |
| CN101283999B (en) | Medicinal composition mainly for curing cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN101759672B (en) | Salvianolic acid B in radix salviae miltiorrhizae | |
| CN101584743A (en) | Method for preparing Chinese traditional medicinal compound salvia miltiorrhiza preparation for curing cardiovascular and cerebrovascular diseases | |
| CN102086223B (en) | Method for preparing ginsenoside Rg1 | |
| CN102100737B (en) | Medicinal composition containing general ginsenoside and total salvianolic acid and preparation method thereof | |
| CN101006975B (en) | An oral medicine preparation containing salvianolic acid A and extract of panax natoginseng, and its preparation method and application | |
| CN102085206B (en) | Medicinal composition | |
| CN101428050B (en) | Active composition for treating thrombus, cardio-cerebrovascular system diseases | |
| CN101292987B (en) | Pharmaceutical combination | |
| CN101759751A (en) | Ginsenoside Rg 1 containing ginsenoside Re impurity | |
| CN101390871B (en) | Ginsenoside Rb1 containing impurity ginsenoside Rd | |
| CN101293009A (en) | Pharmaceutical composition | |
| CN101445544A (en) | Method for preparing ginsenoside Rb<1> | |
| CN103919759B (en) | A kind of containing danshensu sodium, the pharmaceutical composition of salvia miltiorrhiza tanshinoate F and preparation thereof | |
| CN101926848B (en) | Medicinal composition for treating heart cerebrovascular diseases and preparation thereof | |
| CN101390870A (en) | Ginsenoside Rb1 containing impurity ginsenoside Rc | |
| CN104069312B (en) | Treat Chinese medicine composition of apoplexy and preparation method thereof, pharmaceutical preparation and application | |
| WO2023125719A1 (en) | Veronica undulata extract as well as preparation method therefor and use thereof | |
| CN100556419C (en) | A kind of dispersible tablet that contains Radix Salviae Miltiorrhizae and Sanchi effective-component and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| DD01 | Delivery of document by public notice |
Addressee: Beijing Bencao Tianyuan Pharmaceutical Research Institute Document name: Notification to Pay the Fees |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Beijing Bencao Tianyuan Pharmaceutical Research Institute Document name: Notification to Pay the Fees |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Sun Dejie Document name: payment instructions |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Sun Dejie Document name: payment instructions |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Beijing Bencao Tianyuan Pharmaceutical Research Institute Person in charge of patentsThe principal of patent Document name: Patent termination notice |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Sun Dejie Document name: Notice of Correction for Handling the Procedure for Restoration of Rights |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Sun Dejie Document name: Notice of Approval for Restoration of Rights Request |
|
| DD01 | Delivery of document by public notice |